Option chain shows key data for Nixxy's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Nixxy.

Nixxy (NASDAQ:NIXX) Stock, Option Chain

Nixxy

Recruiter.Com Group

Nixxy Inc formerly Recruiter.Com Group Inc is a hiring platform for the network of recruiters. It empowers businesses to recruit specialized talent faster with virtual teams of recruiters and AI job-matching technology. The Recruiter.com network of over 28,000 small and independent recruiters utilize a web platform, complete with AI-driven job matching, to recruit talent faster. Its Recruiters On Demand provides businesses of all sizes access to virtual recruiters specialized by vertical industries to source, engage, and hire talent on an as-needed basis.

Stocks.Watch_.Shutterstock

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

CERS

GEVO

IRDM

LCID

NIXX

S&amp;P 5000 Edges Higher; US Crude Oil Inventories Fall

Crude Oil Edges Higher; US Retail Sales Top Expectations

5 Things To Watch As US Stocks Set For Flattish Start

Guidance

Small Cap

Movers

Nixxy shares surge on updates regarding acquisition strategy, technology focus, and goal of reaching $1 billion enterprise value.

Nixxy&#39;s Acquisition Spree Heats Up: Shoots For $1B Valuation

Nixxy Inc

Baird analyst Tristan Gerra maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Outperform and lowers the price target from $150 to $130.

Price Target

Analyst Ratings

Baird Maintains Outperform on Micron Technology, Lowers Price Target to $130

Keybanc analyst Eric Heath downgrades C3.ai (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) from Sector Weight to Underweight and announces $29 price target.

Downgrades

Keybanc Downgrades C3.ai to Underweight, Announces $29 Price Target

Vladimir Putin, the President of Russia, has <a href="https://www.benzinga.com/news/global/24/11/41865062/putin-congratulates-trump-on-2024-election-victory-russian-leader-said-president-elect-manly-for-how-he-handled-assassination-attempt">shown his readiness to initiate talks</a> with the incoming U.S. President Donald Trump. 
What Happened: In his annual televised press conference held in Moscow, Putin stated his readiness to engage in dialogue with Trump,  <a href="https://www.bloomberg.com/news/articles/2024-12-19/putin-says-he-s-ready-to-meet-trump-hasn-t-seen-syria-s-assad">Bloomberg</a> on Thursday.
&#8220;I&#8217;m ready for it, of course, at any time. And I&#8217;ll be ready to meet if he wants,&#8221; he said. Trump, who is due to begin his second term as US president on Jan.20, has expressed his intent to resolve the ongoing war between Russia and Ukraine, which has been ongoing for nearly three years.
Trump Campaign did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/equities/24/12/42522048/jim-cramer-warns-nvidias-vicious-and-fast-reversal-is-coming-amid-174-surge-this-year-and-china-antitrust-probe?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Jim Cramer Warns Nvidia&#8217;s &#8216;Vicious&#8217; And &#8216;Fast&#8217; Reversal Is Coming Amid 174% Surge This Year And China Ant</a>
Trump has also hinted at his expectation for Putin to be open to a deal. However, the details of how he intends to bring both parties to the negotiation table and the terms of the potential agreement remain undisclosed.
Why It Matters: Putin also disclosed that he has not had any interaction with the deposed Syrian President Bashar al-Assad, who sought refuge in Moscow earlier this month. &#8220;I haven&#8217;t seen President Assad since his arrival in Moscow,&#8221; Putin stated. He also mentioned his plans to meet with Assad to discuss various matters, including the case of Austin Tice, the American journalist who has been missing. Earlier, Trump <a href="https://www.benzinga.com/news/global/24/12/42380085/trump-on-assads-fall-putin-was-not-interested-in-protecting-him-any-longer">commented on Putin&#8217;s lack of interest</a> in protecting Assad following the dictator&#8217;s fall.
Meanwhile, a book by journalist Bob Woodward in October<a href="https://www.benzinga.com/general/politics/24/10/41235596/trump-secretly-stayed-in-contact-with-putin-after-leaving-office-upcoming-bob-woodward-book-alle"> reportedly alleged that Trump and Russian President </a>Putin have spoken as many as seven times since 2021.
Read Next: <a href="https://www.benzinga.com/trading-ideas/movers/24/12/42516580/ionq-quantum-computing-and-rigetti-computing-shares-are-soaring-monday-whats-going-on?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">IonQ, Quantum Computing And Rigetti Computing Shares Are Soaring Monday: What&#8217;s Going On?</a>
Image via Kremlin

Politics

General

Russian President Says He's Willing To Meet Trump 'At Any Time' For Dialogue

Baird analyst Mark Altschwager maintains Birkenstock Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) with a Outperform and raises the price target from $65 to $72.

BIRK

Baird Maintains Outperform on Birkenstock Holding, Raises Price Target to $72

Chardan Capital analyst Daniil Gataulin maintains Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) with a Buy and maintains $11 price target.

CGTX

Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $11 Price Target

Biotech

Health Care

PHIO

Phio Pharmaceuticals Announced That The Safety Monitoring Committee Recommended Dose Escalation In Its Phase 1B Trial To Evaluate The Safety And Tolerability Of PH-762 For Stages 1, 2, And 4 Cutaneous Squamous Cell Carcinoma, Stage 4 Melanoma, And Stage 4 Merkel Cell Carcinoma

"We are encouraged by the early evidence of responses in patients with cold tumors, including MSS colorectal cancer, reported for the combination of vilastobart and atezolizumab in Phase 1C dose escalation earlier this year, and we look forward to sharing initial Phase 2 data for the combination in MSS CRC at ASCO GI in January," said Katarina Luptakova, M.D., chief medical officer of Xilio.
"In addition, the preliminary Phase 1 data we reported today for XTX301, our tumor-activated IL-12, highlight its promising clinical profile, including no dose-limiting toxicities reported to date and consistent interferon gamma signaling observed throughout treatment cycles."

Xilio To Present Initial Data From Its Ongoing Phase 2 Trial For Vilastobart At ASCO GI; Reports Preliminary Phase 1 Data For XTX301 Showing Improved Tolerability Profile Over Historical Data For rhIL-12

Deutsche Bank analyst David Begleiter maintains PPG Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>) with a Buy and lowers the price target from $150 to $145.

Deutsche Bank Maintains Buy on PPG Indus, Lowers Price Target to $145

The most oversold stocks in the industrials sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Paychex Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>)</h3>
<ul>
<li>On Nov. 19, JP Morgan analyst Tien-Tsin Huang maintained Paychex with an Underweight rating and raised the price target from $133 to $139. The company's stock fell around 4% over the past five days and has a <a href="https://www.benzinga.com/quote/PAYX">52-week low of $114.72</a>.</li>
<li>RSI Value: 29.58&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>PAYX Price Action: Shares of Paychex fell 3.2% to close at $135.86 on Wednesday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121924&amp;t=be2bearmibe3na1">latest PAYX news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="908" height="850" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074317/image-164.png" alt="" class="wp-image-699579" style="width:617px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074317/image-164.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074317/image-164-300x281.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074317/image-164-768x719.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
<h3 class="wp-block-heading">Sunrun Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Dec. 17, Goldman Sachs analyst Brian Lee maintained Sunrun with a Buy and lowered the price target from $19 to $17. The company's stock fell around 12% over the past five days and <a href="https://www.benzinga.com/quote/RUN">has a 52-week low</a> of $9.13.</li>
<li>RSI Value: 28.40</li>
<li>RUN Price Action: Shares of Sunrun fell 9.1% to close at $9.15 on Wednesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121924&amp;t=be2bearmibe3na1"> trend in RUN stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="916" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074410/image-165.png" alt="" class="wp-image-699581" style="width:630px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074410/image-165.png 916w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074410/image-165-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074410/image-165-768x706.png 768w" sizes="(max-width: 916px) 100vw, 916px" /></a></figure>
<h3 class="wp-block-heading">A O Smith Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOS#NYSE">AOS</a>)</h3>
<ul>
<li>On Dec. 11, Stifel analyst Nathan Jones maintained A.O. Smith with a Buy and lowered the price target from $91 to $90. The company's stock fell around 5% over the past five days and has a 52-week <a href="https://www.benzinga.com/quote/AOS">low of $68.89.</a></li>
<li>RSI Value: 25.09</li>
<li>AOS Price Action: Shares of A O Smith fell 2.7% to close at $68.91 on Wednesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121924&amp;t=be2bearmibe3na1">breakout in AOS shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="927" height="836" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074507/image-166.png" alt="" class="wp-image-699582" style="width:567px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074507/image-166.png 927w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074507/image-166-300x271.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074507/image-166-768x693.png 768w" sizes="(max-width: 927px) 100vw, 927px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42553288/top-3-tech-and-telecom-stocks-that-may-crash-this-month">Top 3 Tech And Telecom Stocks That May Crash This Month</a></li>
</ul>

Long Ideas

Pre-Market Outlook

PAYX

Top 3 Industrials Stocks Which Could Rescue Your Portfolio For December

Deutsche Bank analyst David Begleiter maintains Axalta Coating Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXTA#NYSE">AXTA</a>) with a Buy and lowers the price target from $44 to $42.

AXTA

Deutsche Bank Maintains Buy on Axalta Coating Sys, Lowers Price Target to $42

Wells Fargo analyst Derek Archila downgrades Cabaletta Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) from Overweight to Equal-Weight and lowers the price target from $12 to $6.

CABA

Wells Fargo Downgrades Cabaletta Bio to Equal-Weight, Lowers Price Target to $6

Keybanc analyst Eric Heath upgrades Fortinet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) from Sector Weight to Overweight and announces $115 price target.

Upgrades

FTNT

Keybanc Upgrades Fortinet to Overweight, Announces $115 Price Target

Deutsche Bank analyst Steve Powers maintains General Mills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) with a Hold and lowers the price target from $72 to $68.

Deutsche Bank Maintains Hold on General Mills, Lowers Price Target to $68

Deutsche Bank analyst Krisztina Katai maintains Birkenstock Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) with a Buy and raises the price target from $65 to $66.

Deutsche Bank Maintains Buy on Birkenstock Holding, Raises Price Target to $66

Wells Fargo analyst Derek Archila upgrades C4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCCC#NASDAQ">CCCC</a>) from Equal-Weight to Overweight and raises the price target from $8 to $12.

CCCC

Wells Fargo Upgrades C4 Therapeutics to Overweight, Raises Price Target to $12

NLSP

NLS Pharmaceutics And Kadimastem In Collaboration With iTolerance Announced That Request For Pre-Investigational New Drug Meeting Has Been Submitted To The FDA For iTOL102 For Type 1 Diabetes

The Company's net income for 1H 2024 was $44,000 as compared to net loss of $255,000 for 1H 2023 resulting from increase in gross profit.

CLWT

Euro Tech Holdings H1 2024 Revenue $7.259M, Down From $7.957M YoY

Keybanc analyst Eric Heath upgrades Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) from Sector Weight to Overweight and announces $115 price target.

OKTA

Keybanc Upgrades Okta to Overweight, Announces $115 Price Target

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is reportedly in early discussions with officials of the city of Austin, Texas, to roll out its <a href="https://www.benzinga.com/topic/tesla-cybercab">autonomous vehicles for testing</a> as early as 2025.
What Happened: Elon Musk-led Tesla's driverless vehicle ambitions could get a boost if its discussions with Austin City bear fruit.
According to a <a href="https://www.bloomberg.com/news/articles/2024-12-19/tesla-sounds-out-austin-officials-about-long-promised-driverless-fleets">report</a> by Bloomberg, a Tesla employee has been in touch with Austin city officials since as early as May to create a safety framework for deploying driverless fleets.
Reacting to the news, the Tesla stock surged over 3% in premarket trading to hover at $453.91, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
See Also: <a href="https://www.benzinga.com/tech/24/12/42570564/tesla-says-powerwall-owners-generated-4-5-twh-of-solar-energy-this-year-amid-energy-segment-revenue-boom">Tesla Says Powerwall Owners Generated 4.5 TWh Of Solar Energy This Year Amid Energy Segment Revenue Boom</a>
Why It Matters: Tesla's autonomous driving ambitions have been a key area of focus as analysts determine the impact of a driverless fleet on the EV giant's prospects.
Wedbush analyst Dan Ives and long-time Tesla bull thinks the Tesla stock could hit the <a href="https://www.benzinga.com/24/12/42455654/wedbush-securities-sees-tesla-touching-2-trillion-market-cap-by-2025-end-apple-microsoft-nvidia-to-join-4-trillion-market-cap-club-next-year-says-analyst">$2 trillion market capitalization mark</a> by the end of 2025, in a bull-case scenario.
"We believe with the autonomous story at Tesla worth $1 trillion alone that in a bull case scenario by the end of 2025, Tesla could achieve a $2 trillion market cap threshold," Ives said. "FSD, autonomous, and the launch of Cybercab for early 2026 are keys for Tesla.&#8221;
Tesla has also been <a href="https://www.benzinga.com/tech/24/11/42230503/tesla-cybercab-spotted-testing-in-giga-texas-facility">spotted testing the Cybercab</a> at the Giga Texas facility. A video shared on social media showcased the Cybercab navigating traffic autonomously within the premises.
Price Action: On a year-to-date basis, the stock is up 77.2%. <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">Here&#8217;s what other analysts are saying.</a>
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42571913/tesla-registrations-drop-by-nearly-41-in-november-in-eu-dragging-down-optimism-for-over-500000-ev-deliveries-in-q4">Tesla EU Registrations Plunge 41% In November, Casting Shadow On Q4 Target Of Over 500,000 EV Deliveries</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Tesla

Tech

TSLA

Tesla Reportedly In Talks With Austin To Bring Autonomous Vehicles To Texas Roads: Elon Musk-Led EV Giant Rises 3% In Pre Market

Wells Fargo analyst Steven Cahall upgrades Tegna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGNA#NYSE">TGNA</a>) from Equal-Weight to Overweight and announces $23 price target.

TGNA

Wells Fargo Upgrades Tegna to Overweight, Announces $23 Price Target

Nixxy shares fall as co reports CognoGroup spin-off plans

Recruiter.Com Group, Inc. ( ($NIXX) ) has released its Q3 earnings. Here is a breakdown of the information Recruiter.Com Group, Inc. presented to i...

Nixxy, Inc. Reports Shift and Challenges in Latest Earnings

Nixxy (NIXX) is offering up to 20M shares of common stock at an assumed offering price of $3.21 per share, which is equal average of the high and l...

Nixxy files to sell 20M shares of common stock

Nixxy ( ($NIXX) ) has shared an update. Granger Whitelaw has resigned from his roles as a member of the Board of Directors and as Chief Executive O...

Nixxy CEO Granger Whitelaw Resigns, Successor Search Begins

Nixxy CEO Granger Whitelaw resigns

On December 12, Granger Whitelaw resigned from his positions as member of the Board of Directors of Nixxy (NIXX) effective immediately, and as Chie...

Comments

Nixxy

Nixxy (NIXX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga